Crushing debt forced Unigene Laboratories Inc. into bankruptcy earlier this year, but its promising Peptelligence delivery technology has found a new home in start-up Enteris Biopharma Inc., which launched recently to develop oral formulations of both peptide drugs and currently injectable-only small molecules.